Add listing
    0
    Add listing

    SEAL Therapeutics AG Verified listing

    • Swiss Biotech Association
      Not a member

    SEAL Therapeutics develops an innovative gene therapy approach that overcomes the functional defects causing LAMA2-related muscular dystrophy. The approach involves AAV-based delivery of specifically designed artificial linker proteins to compensate for the missing laminin-alpha 2 in muscle fibers.

    Location
    Additional address info
    • c/o Prof. Dr. Markus A. Rüegg, Biozentrum
    Canton
    Facts & figures
    • Type of organization
      Private company
    • Year of foundation
      2021
    • Number of employees in Switzerland
      1-9
    Key business

    You may also be interested in